Dyadic International Inc

NASDAQ:DYAIUnited States

Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.

Contact Information

Headquarters

1044 NORTH U.S. HIGHWAY ONE, SUITE 201JUPITER, FL, United States 33477

Phone

561-743-8333

Fax

561-743-8343

Executives

Independent Chairman of the Board

Patrick Lucy

President, Chief Executive Officer, Director

Mark Emalfarb

Chief Financial Officer

Ping Rawson

Chief Operating Officer

Joseph Hazelton

Vice President of Research and Business Development

Ronen Tchelet